Gilead Sciences (GILD) Non-Current Deffered Revenue (2009 - 2013)

Gilead Sciences has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $22.0 million in Q4 2013.

• For the quarter ending Q4 2013, Non-Current Deffered Revenue rose 7.05% year-over-year to $22.0 million; the trailing twelve-month figure through Dec 2013 stood at $22.0 million (up 7.05% YoY), and the FY2013 full-year result was $22.0 million, up 7.05% from the prior year.
• Non-Current Deffered Revenue for Q4 2013 stood at $22.0 million, down from $25.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $53.4 million in Q2 2009, with the low at $20.5 million in Q4 2012.
• Historically, Non-Current Deffered Revenue has averaged $32.2 million across 5 years, with a median of $31.1 million in 2011.
• Annual changes were most pronounced in 2012 — Non-Current Deffered Revenue sank 39.96% — and 2013, when it grew 21.89%.
• Gilead Sciences' Non-Current Deffered Revenue stood at $43.0 million in 2009, then retreated by 23.66% to $32.8 million in 2010, then retreated by 2.97% to $31.9 million in 2011, then slumped by 35.58% to $20.5 million in 2012, then gained by 7.05% to $22.0 million in 2013.
• The last three Non-Current Deffered Revenue figures came in at $22.0 million (Q4 2013), $25.4 million (Q3 2013), and $28.8 million (Q2 2013), per Business Quant data.